This page has only limited features, please log in for full access.

Prof. Susana Godina
Universidad Autónoma de Zacatecas

Basic Info


Research Keywords & Expertise

0 Immunology
0 Toxicology
0 drug toxicity
0 Immunology and cancer immunity
0 toxicology pesticides

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

Química de profesión, con estudios de posgrado en Toxicología e Inmunología. Profesor investigador de la Unviersidad Autónoma de Zacatecas.

Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Review
Published: 22 July 2021 in Cells
Reads 0
Downloads 0

Cancer is one of the leading public health issues worldwide, and the number of cancer patients increases every day. Particularly, cervical cancer (CC) is still the second leading cause of cancer death in women from developing countries. Thus, it is essential to deepen our knowledge about the molecular pathogenesis of CC and propose new therapeutic targets and new methods to diagnose this disease in its early stages. Differential expression analysis using high-throughput techniques applied to biological samples allows determining the physiological state of normal cells and the changes produced by cancer development. The cluster of differential molecular profiles in the genome, the transcriptome, or the proteome is analyzed in the disease, and it is called the molecular signature of cancer. Proteomic analysis of biological samples of patients with different grades of cervical intraepithelial neoplasia (CIN) and CC has served to elucidate the pathways involved in the development and progression of cancer and identify cervical proteins associated with CC. However, several cervical carcinogenesis mechanisms are still unclear. Detecting pathologies in their earliest stages can significantly improve a patient’s survival rate, prognosis, and recurrence. The present review is an update on the proteomic study of CC.

ACS Style

Fátima Martínez-Rodríguez; Jared Limones-González; Brenda Mendoza-Almanza; Edgar Esparza-Ibarra; Perla Gallegos-Flores; Jorge Ayala-Luján; Susana Godina-González; Eva Salinas; Gretel Mendoza-Almanza. Understanding Cervical Cancer through Proteomics. Cells 2021, 10, 1854 .

AMA Style

Fátima Martínez-Rodríguez, Jared Limones-González, Brenda Mendoza-Almanza, Edgar Esparza-Ibarra, Perla Gallegos-Flores, Jorge Ayala-Luján, Susana Godina-González, Eva Salinas, Gretel Mendoza-Almanza. Understanding Cervical Cancer through Proteomics. Cells. 2021; 10 (8):1854.

Chicago/Turabian Style

Fátima Martínez-Rodríguez; Jared Limones-González; Brenda Mendoza-Almanza; Edgar Esparza-Ibarra; Perla Gallegos-Flores; Jorge Ayala-Luján; Susana Godina-González; Eva Salinas; Gretel Mendoza-Almanza. 2021. "Understanding Cervical Cancer through Proteomics." Cells 10, no. 8: 1854.

Journal article
Published: 14 December 2020 in International Journal of Environmental Research and Public Health
Reads 0
Downloads 0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID-19), a highly contagious infectious disease that has caused many deaths worldwide. Despite global efforts, it continues to cause great losses, and leaving multiple unknowns that we must resolve in order to face the pandemic more effectively. One of the questions that has arisen recently is what happens, after recovering from COVID-19. For this reason, the objective of this study is to identify the risk of presenting persistent symptoms in recovered from COVID-19. This case-control study was conducted in one state of Mexico. Initially the data were obtained from the participants, through a questionnaire about symptoms that they had at the moment of the interview. Initially were captured the collected data, to make a dataset. After the pre-processed using the R project tool to eliminate outliers or missing data. Obtained finally a total of 219 participants, 141 recovered and 78 controls. It was used confidence level of 90% and a margin of error of 7%. From results it was obtained that all symptoms have an associated risk in those recovered. The relative risk of the selected symptoms in the recovered patients goes from 3 to 22 times, being infinite for the case of dyspnea, due to the fact that there is no control that presents this symptom at the moment of the interview, followed by the nausea and the anosmia with a RR of 8.5. Therefore, public health strategies must be rethought, to treat or rehabilitate, avoiding chronic problems in patients recovered from COVID-19.

ACS Style

Carlos E. Galván-Tejada; Cintya Fabiola Herrera-García; Susana Godina-González; Karen E. Villagrana-Bañuelos; Juan Daniel De Luna Amaro; Karla Herrera-García; Carolina Rodríguez-Quiñones; Laura A. Zanella-Calzada; Julio Ramírez-Barranco; Jocelyn L. Ruiz De Avila; Fuensanta Reyes-Escobedo; José M. Celaya-Padilla; Jorge I. Galván-Tejada; Hamurabi Gamboa-Rosales; Mónica Martínez-Acuña; Alberto Cervantes-Villagrana; Bruno Rivas-Santiago; Irma E. Gonzalez-Curiel. Persistence of COVID-19 Symptoms after Recovery in Mexican Population. International Journal of Environmental Research and Public Health 2020, 17, 9367 .

AMA Style

Carlos E. Galván-Tejada, Cintya Fabiola Herrera-García, Susana Godina-González, Karen E. Villagrana-Bañuelos, Juan Daniel De Luna Amaro, Karla Herrera-García, Carolina Rodríguez-Quiñones, Laura A. Zanella-Calzada, Julio Ramírez-Barranco, Jocelyn L. Ruiz De Avila, Fuensanta Reyes-Escobedo, José M. Celaya-Padilla, Jorge I. Galván-Tejada, Hamurabi Gamboa-Rosales, Mónica Martínez-Acuña, Alberto Cervantes-Villagrana, Bruno Rivas-Santiago, Irma E. Gonzalez-Curiel. Persistence of COVID-19 Symptoms after Recovery in Mexican Population. International Journal of Environmental Research and Public Health. 2020; 17 (24):9367.

Chicago/Turabian Style

Carlos E. Galván-Tejada; Cintya Fabiola Herrera-García; Susana Godina-González; Karen E. Villagrana-Bañuelos; Juan Daniel De Luna Amaro; Karla Herrera-García; Carolina Rodríguez-Quiñones; Laura A. Zanella-Calzada; Julio Ramírez-Barranco; Jocelyn L. Ruiz De Avila; Fuensanta Reyes-Escobedo; José M. Celaya-Padilla; Jorge I. Galván-Tejada; Hamurabi Gamboa-Rosales; Mónica Martínez-Acuña; Alberto Cervantes-Villagrana; Bruno Rivas-Santiago; Irma E. Gonzalez-Curiel. 2020. "Persistence of COVID-19 Symptoms after Recovery in Mexican Population." International Journal of Environmental Research and Public Health 17, no. 24: 9367.

Review
Published: 06 May 2020 in Toxins
Reads 0
Downloads 0

Bacillus thuringiensis (Bt) is a ubiquitous bacterium in soils, insect cadavers, phylloplane, water, and stored grain, that produces several proteins, each one toxic to different biological targets such as insects, nematodes, mites, protozoa, and mammalian cells. Most Bt toxins identify their particular target through the recognition of specific cell membrane receptors. Cry proteins are the best-known toxins from Bt and a great amount of research has been published. Cry are cytotoxic to insect larvae that affect important crops recognizing specific cell membrane receptors such as cadherin, aminopeptidase-N, and alkaline phosphatase. Furthermore, some Cry toxins such as Cry4A, Cry4B, and Cry11A act synergistically with Cyt toxins against dipteran larvae vectors of human disease. Research developed with Cry proteins revealed that these toxins also could kill human cancer cells through the interaction with specific receptors. Parasporins are a small group of patented toxins that may or may not have insecticidal activity. These proteins could kill a wide variety of mammalian cancer cells by recognizing specific membrane receptors, just like Cry toxins do. Surface layer proteins (SLP), unlike the other proteins produced by Bt, are also produced by most bacteria and archaebacteria. It was recently demonstrated that SLP produced by Bt could interact with membrane receptors of insect and human cancer cells to kill them. Cyt toxins have a structure that is mostly unrelated to Cry toxins; thereby, other mechanisms of action have been reported to them. These toxins affect mainly mosquitoes that are vectors of human diseases like Anopheles spp (malaria), Aedes spp (dengue, zika, and chikungunya), and Culex spp (Nile fever and Rift Valley fever), respectively. In addition to the Cry, Cyt, and parasporins toxins produced during spore formation as inclusion bodies, Bt strains also produce Vip (Vegetative insecticidal toxins) and Sip (Secreted insecticidal proteins) toxins with insecticidal activity during their vegetative growth phase.

ACS Style

Gretel Mendoza-Almanza; Edgar L. Esparza-Ibarra; Jorge L. Ayala-Luján; Marisa Mercado-Reyes; Susana Godina-González; Marisa Hernández-Barrales; Jorge Olmos-Soto. The Cytocidal Spectrum of Bacillus thuringiensis Toxins: From Insects to Human Cancer Cells. Toxins 2020, 12, 301 .

AMA Style

Gretel Mendoza-Almanza, Edgar L. Esparza-Ibarra, Jorge L. Ayala-Luján, Marisa Mercado-Reyes, Susana Godina-González, Marisa Hernández-Barrales, Jorge Olmos-Soto. The Cytocidal Spectrum of Bacillus thuringiensis Toxins: From Insects to Human Cancer Cells. Toxins. 2020; 12 (5):301.

Chicago/Turabian Style

Gretel Mendoza-Almanza; Edgar L. Esparza-Ibarra; Jorge L. Ayala-Luján; Marisa Mercado-Reyes; Susana Godina-González; Marisa Hernández-Barrales; Jorge Olmos-Soto. 2020. "The Cytocidal Spectrum of Bacillus thuringiensis Toxins: From Insects to Human Cancer Cells." Toxins 12, no. 5: 301.

Journal article
Published: 27 June 2010 in Inflammation Research
Reads 0
Downloads 0

Monocyte locomotion inhibitory factor (MLIF), an amebic peptide with antiinflammatory properties, was evaluated in collagen-induced arthritis (CIA) to test its effects on the onset and acute inflammatory response of arthritis.

ACS Style

Susana Godina-Gonzalez; Janette Furuzawa-Carballeda; Dolores Utrera-Barillas; Jorge Alcocer-Varela; Luis Manuel Teran; Mónica Vázquez-Del Mercado; Yelda A. Leal; Isabel Alvarado-Cabrero; Juan R. Velazquez. Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in CIA mouse model by downregulation of cell adhesion, inflammation/chemotaxis, and matrix metalloproteinases genes. Inflammation Research 2010, 59, 1041 -1051.

AMA Style

Susana Godina-Gonzalez, Janette Furuzawa-Carballeda, Dolores Utrera-Barillas, Jorge Alcocer-Varela, Luis Manuel Teran, Mónica Vázquez-Del Mercado, Yelda A. Leal, Isabel Alvarado-Cabrero, Juan R. Velazquez. Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in CIA mouse model by downregulation of cell adhesion, inflammation/chemotaxis, and matrix metalloproteinases genes. Inflammation Research. 2010; 59 (12):1041-1051.

Chicago/Turabian Style

Susana Godina-Gonzalez; Janette Furuzawa-Carballeda; Dolores Utrera-Barillas; Jorge Alcocer-Varela; Luis Manuel Teran; Mónica Vázquez-Del Mercado; Yelda A. Leal; Isabel Alvarado-Cabrero; Juan R. Velazquez. 2010. "Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in CIA mouse model by downregulation of cell adhesion, inflammation/chemotaxis, and matrix metalloproteinases genes." Inflammation Research 59, no. 12: 1041-1051.